[Efficacy of iron saturated recombinant human lactoferrin on alleviating iron deficiency anemia in rats].
To investigate the effect of iron saturated recombinant human lactoferrin (Fe-rhLf) on treating iron deficiency anemia (IDA). SD rats received iron deficient diet and deionized water during the whole experiment. After 4 weeks, the rats with hemoglobin less than 100 g/L were selected and divided into 5 groups randomly. IDA group received 100 mg/(kg×d) casein dissolved in deionized water intragastrically; FeSO4 group received 5.43 mg/(kg×d) [2.0 mg/(kg×d) iron]+100 mg/(kg×d) casein intragastrically; low dose Fe-rhLf group received 75.53 mg/(kg×d) Fe-rhLf [0.5 mg/(kg×d) iron] +75 mg/(kg×d) casein intragastrically; middle dose group received 151.06 mg/(kg×d) Fe-rhLf [1.0 mg/(kg×d) iron]+50 mg/(kg×d) casein intragastrically; high dose group received 302.11 mg/(kg×d) Fe-rhLf [2.0 mg/(kg×d) iron] intragastrically. After 30 days of intervention, the rats' blood was collected and used to do the routine blood test, serum iron and serum anti-oxidants test. The liver hepcidin and ferroportin mRNA expression was tested by real time PCR. Compared with the animals in the IDA group, Fe-rhLf could increase weight significantly (P<0.05), hematological parameters, like hemoglobin (P<0.01) and red blood cell count (P<0.01) recovered significantly. Compared with animals in FeSO4 group, high dose Fe-rhLf could improve hemoglobin significantly (P<0.05). The liver hepcidin expression was up regulated and ferroportin down regulated. Fe-rhLf has a significant effect on treating iron deficiency anemia.